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Background: People who inject drugs (PWID) are underserved by health providers but pharmacies may be their
most accessible care settings.
Methods: Studies in the U.S., Russia, Vietnam, China, Canada and Mexico employed a three-level (macro-, meso-,
and micro-) model to assess feasibility of expanded pharmacy services for PWID. Studies employed qualitative and
quantitative interviews, review of legal and policy documents, and information on the knowledge, attitudes, and
practices of key stakeholders.
Results: Studies produced a mixed assessment of feasibility. Provision of information and referrals by pharmacies is
permissible in all study sites and sale and safe disposal of needles/syringes by pharmacies is legal in almost all sites,
although needle/syringe sales face challenges related to attitudes and practices of pharmacists, police, and other
actors. Pharmacy provision of HIV testing, hepatitis vaccination, opioid substitution treatment, provision of naloxone
for drug overdose, and abscess treatment, face more serious legal and policy barriers.
Discussion: Challenges to expanded services for drug users in pharmacies exist at all three levels, especially the
macro-level characterized by legal barriers and persistent stigmatization of PWID. Where deficiencies in laws, policies,
and community attitudes block implementation, stakeholders should advocate for needed legal and policy changes
and work to address community stigma and resistance. Laws and policies are only as good as their implementation, so
attention is also needed to meso- and micro- levels. Policies, attitudes, and practices of police departments and
pharmacy chains as well as knowledge, attitudes, and practices of individual PWID, individual pharmacies, and police
officers should support rather than undermine positive laws and expanded services. Despite the challenges, pharmacies
remain potentially important venues for delivering health services to PWID.Background
Almost 150 countries on all continents had reported
injection drug use by 2007 and 120 of these had reported
related HIV infections [1]. According to estimates for
2010–2011, HIV prevalence among the 14–16 million
people who inject drugs (PWID) worldwide is 12% with
wide variation across regions [2,3]. Injection drug use is
driving HIV epidemics in many countries in Asia, the
Middle East, and Eastern Europe and there are continuing* Correspondence: ted_hammett@abtassoc.com
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unless otherwise stated.epidemics of HIV and other parenterally transmitted vi-
ruses such as hepatitis C among PWID in many locations
worldwide [4-6]. In many countries, controlling HIV/
AIDS and hepatitis epidemics depends on reducing trans-
mission among PWID and other people who use drugs.
For various reasons including widespread stigma and
discrimination, people who use drugs are generally
underserved by and/or reluctant to visit traditional
health providers – physicians, health clinics, and hospi-
tals [7]. In developed countries, many drug users rely on
paramedic and/or emergency room care when they are
seriously ill, suffer overdose, or experience other healthral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pharmacies are a type of health facility that is commonly
accessed by drug users but their use is often limited to
the purchase of needles/syringes and other items related
to drug injection [8-10]. Because drug users frequently
visit pharmacies there is the potential for pharmacies to
provide expanded health services for them [11].
To assess the potential for pharmacies to become venues
for expanded health services for PWID, including services
related to HIV/AIDS, hepatitis, and substance use preven-
tion and treatment, the National Institute on Drug Abuse,
U.S. National Institutes of Health funded linked grants
from a consortium of investigators from six sites in four
countries – the United States (Boston, Providence, and
San Francisco), Russia (St. Petersburg), Vietnam (Ha Giang
City), and China (Xichang, Sichuan Province) – to conduct
mixed-methods feasibility studies. These sites were se-
lected to provide a range of geographic settings and per-
ceived attitudes towards harm reduction and other
services for drug injectors.
The feasibility studies were carried out between 2009 and
2012 with investigators conducting similar studies in Van-
couver, Canada and Tijuana, Mexico joining the researchTable 1 Injection drug use, HIV, and research methods in stud
Site Est. n PWID Predominant
injected drug(s)
Est. HIV
among
Original sites funded under linked NIDA grants
Boston 10,064a heroin 4.5%b-8.4
Providence 2,137a opiates 5.3%b
San Francisco 17,000 heroin,
methamphetamine
12%
Ha Giang, Vietnam 1,000 heroin 18%
St. Petersburg, Russia 83,000g heroin 44%-59%
Xichang, China 2,250 heroin 18%
Additional sites
Tijuana, Mexico 6,400-10,000 heroin, heroin/
methamphetamine
4%i
Vancouver, Canada 10,000-15,000 Cocaine, heroin,
methamphetamine
17% (200
aBased on methods in Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, Gos
in large U.S. metropolitan areas from 1992 to 2002. J Urban Health 2008, 85: 32
bTempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence
1992–2002. J Urban Health 2009, 86: 132–154.
cNational Health Behavior Survey, 2009.
dCases reported in 2010, from Massachusetts Department of Public Health, 2012 Ep
eCases reported 2008–2010, from Rhode Island Department of Public Health, 2010 E
fNewly reported cases in 2010, includes PWID and MSM/PWID.
gHeimer R, White E. Estimation of the number of injection drug users in St. Pete
hNiccolai LM, Shcherbakova IS, Toussova OV, Kozlov AP, Heimer R. The potential fo
and HIV prevalence among drug users (DUs) and their non-DU sex partners. J
Odinokova V, White E, Rusakova MM, Smolskaya TT, Levina OS. Individual-, networ
who inject drugs in eight Russian cities. BMJ Open, In press.
IStrathdee SA, Lozada R, Ojeda VD, Pollini RA, Brouwer KC, Vera A, Cornelius W, Ngu
effects of migration and deportation on HIV infection among male and female
3(7):e2690.doi:0.1371/journal.pone.0002690.group in 2011, bringing the number of countries repre-
sented to six and the number of sites to eight. Table 1 pre-
sents basic statistics on the epidemics of injection drug use
and HIV in these eight sites.
The projects aimed to assess current pharmacy services
and the potential for their expansion and to identify bar-
riers to and facilitators of such expanded services. These
factors included pharmacists’ attitudes and possible inter-
ference from law enforcement and policy makers. In this
paper, we assess further the feasibility of pharmacies to
implement expanded services for PWID based on the legal
and policy frameworks of the six countries and other inhi-
biting and facilitating factors.Methods
The multi-site feasibility studies of expanded pharmacy ser-
vices for drug users employed mixed methods: qualitative
and quantitative interviews with key stakeholders in health,
police, and other sectors, including government officials,
health care providers, pharmacists, and PWID, as well as
review of relevant legal and policy documents and literature
in the field.y sites
prevalence
PWID
Est. % of HIV infections
attributable to drug use
Methods
%c 9%d Formative research, qualitative
interviews, quantitative surveys,
review of legal and
policy documents
6%e
22%f
>50%
h 76%
60%
12% Focus groups, quantitative
survey, review of legal and
policy documents
6) 18% (since 2008) Ongoing ethnographic and
qualitative research, review
of legal and policy documents
tnell K. Estimating the prevalence of injection drug users in the U.S. and
3–351.
rates among injection drug users in 96 large US metropolitan areas,
idemiological Profile.
pidemiological Profile.
rsburg, Russia. Drug Alcohol Dependence 2010, 109: 79–83.
r bridging of HIV transmission in Russian Federation: sex risk behaviors
Urban Health 2009, 86(Suppl 1): 131–143; Eritsyan K, Heimer R, Barbour R,
k-, and city-level factors associated with HIV prevalence among people
yen L., Magis-Rodriguez C, Patterson TL, Proyecto El Cuete. Differential
injection drug users in Tijuana, Mexico. PLoS One 2008,
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qualitative interviews, and quantitative surveys in the six ori-
ginal sites. The formative study described the IDU and HIV
epidemic situations. Qualitative interviews were then con-
ducted with PWID and key informants from legal, public
health, and pharmacy systems and quantitative face-to-face
surveys were conducted among PWID and pharmacists. All
data collection investigated current HIV and substance
abuse services for PWID and the needs for additional ser-
vices, explored perceptions of pharmacists regarding new
services for PWID, and identified barriers to pharmacy par-
ticipation in health-related interventions for PWID, includ-
ing possible interference from law enforcement and policy
makers. To explore further the enabling environment for
potentially expanded pharmacy-based interventions, each
site investigator reviewed relevant legal and policy docu-
ments and corporate policies of pharmacy chains bearing
on the implementation of the expanded services identified
in the feasibility studies. The site investigators also provided
information from their own knowledge on street-level prac-
tices that conform to or contradict the laws and policies of
governments and pharmacy chains.
Investigators in the additional sites employed slightly
different methods. In Tijuana, information was obtained
through focus group discussions and a quantitative survey,
as well as review of legal and policy documents. In
Vancouver, review of relevant legal and policy documents
and ongoing ethnographic and qualitative research by the
site investigator were used.
To inform further the analysis of these data, we adapted
a conceptual framework based on elements proposed by
Rhodes [12,13] and Burris [14]. This framework consists
of three levels, defined as follows:
 Macro level: Laws and policies governing pharmacy
operations and procedures; overall legal framework
on drugs and drug paraphernalia; attitudes of the
general community;
 Meso level: Attitudes, policies and practices of
pharmacy chains and police agencies; and
 Micro level: Behavior and attitudes of individual
pharmacies/pharmacists, police officers, and people
who inject drugs.
Results
The feasibility studies found that the following types of
services were most desired by PWID and most likely to
be offered by pharmacies in the future: expanded nee-
dle/syringe sales and distribution; safe disposal of used
needles/syringes; HIV testing; hepatitis B and other vac-
cinations; methadone maintenance and/or other opioid
substitution treatment; provision of naloxone for over-
dose prevention and rescue; skin abscess prevention and
treatment; brief counseling and informational materials;and referrals to HIV/AIDS, substance abuse treatment,
and other services.
Table 2 summarizes the government laws and policies
in the six countries that are most relevant to each of the
proposed expanded services. Table 3 summarizes phar-
macy chains’ policies in the sites where such chains exist
and information on their policies was available: Boston,
Providence, San Francisco, Vancouver, and St. Petersburg.
Needle/syringe sales without prescription are legal in all
study sites, but several have experienced practical barriers
to implementation including attitudes and behaviors of
individual pharmacies, even if the law or their chains
authorize sales. In Vietnam, a female injector said that
pharmacy sellers should be hospitable, because…IDUs
are usually ashamed… If you’re not a hospitable
pharmacy seller, then here come a bad IDU [and] he/
she could shout at you …–49 year-old ethnic female
PWID, injecting for 11 years
In Tijuana, where pharmacy sales of needles/syringes
are legal, focus group discussions with PWID revealed that
many pharmacies refused to sell needles/syringes due to
negative attitudes towards drug users, fear that PWID be-
havior would drive away other customers, and concern
about police response [15]. In a “buy study”, only 28% of
attempted purchases by “mystery shoppers” were success-
ful [16]. Tijuana PWID noted the unpredictability and
inconsistency of pharmacy sales and the commonly nega-
tive attitudes of pharmacy workers:
I mean it can’t be distinguished as one pharmacy or
another, the one that does sell to you and the one that
doesn’t. You go into the pharmacy and there are times
when it does sell to you and others when it doesn’t. –
Male focus group participant.
[W]e’re “tecatos”,….we’re junkies and drug addicts,
many pharmacies don’t want to sell it to you…. I’ve
noticed by how they look at us. –Female focus group
participant.
In San Francisco, under a Disease Prevention Demonstra-
tion Project (DPDP), participating pharmacies may sell up
to 30 needles/syringes at a time but a “buy study”, carried
out as part of the feasibility study presented in this paper,
revealed inconsistent compliance with program provisions
including outright refusals to sell and varying minimum
numbers of needles/syringes required for purchase [17].
In St. Petersburg, Russia, a syringe “buy study”, also
conducted as part of the pharmacy feasibility study in one
central and one peripheral district of the city, found that
half of the pharmacies that refused to sell syringes to
research staff nonetheless reported in a telephone survey
that they stocked syringes [18].
Table 2 Government laws and policies
Sites:
Interventions:
US (Boston) US
(Providence)
US (San Francisco) Canada
(Vancouver)
Mexico (Tijuana) Vietnam (Ha
Giang)
China (Xichang,
Sichuan)
Russia (St. Petersburg)
Needle &
syringe sales/
distribution
MGL ch 94C,
sec 27, 27A,
32 L: authorizes
pharmacy sales
without
prescription at
discretion to
people 18 or
older with no
limits on
quantity
Pharmacies
may sell at
discretion; no
limits on
quantity.
Non-prescription
sales legal (up to 30)
but requires local
approval and
pharmacist
enrollment in
disease prevention
demonstration
project (DPDP).
Pharmacy sales
legal.
Sale at pharmacies
without a
prescription is legal.
Retail non-
prescription sale is
legal; redemption of
vouchers for free
needles & syringes
also legal.
Non-prescription
sale is legal.
Non-prescription sale is legal;
but pharmacies not required
to stock.
Needle &
syringe
disposal
MGL ch 111,
sec 127A:
prohibits
improper
disposal. There
are no legal
barriers to
pharmacies
collecting
waste for
proper disposal.
No legal barrier
to pharmacies
maintaining
sharps
containers.
Sharps must be
disposed in
approved container
and transported to
collection center; no
legal barriers to
sharps containers in
pharmacies;
information on safe
disposal required to
be provided with
needle/syringe sales
under DPDP;
participating
pharmacies must
provide safedisposal
options.
No legal barriers
to pharmacies
collecting used
needles/syringes.
Any facilities
(including
pharmacies) that
generate at least
25 kg of biologic/
infectious waste per
month are required
to dispose of
syringes and other
sharps in a
puncture-proof con-
tainer. Unclear what
rules apply to phar-
macies generating
less than 25 kg per
month.
Not provided for in
Law on Pharmacy
(2005); but
Ordinance on
Private Medical and
Pharmaceutical
Practice (Feb 25,
2003) authorizes
those certified as
private medical
practitioners
(including those
with pharmacy
degrees) to provide
primary health care
and HIV prevention
services (Art. 18).
Needle
exchange and
disposal center
can be set up in
local CDC,
medical
institutes or
other locations.
No legal barriers
for pharmacies
to provide
sharps
containers.
Federal Law #128 (August 8, 2001)
requires a license for collection,
storage, or disposal of hazardous
waste (including used needles & syringes).
HIV testing There is
currently no
standing order
for pharmacists
to conduct HIV
testing.
Pharmacies
need CLIA
waiver to offer
finger prick
testing.
Persons with
required training &
certification may
perform rapid HIV
tests; regulations
would need to be
modified to allow
pharmacies to draw
blood, but not if
testing was done by
an outside
organization.
Provincial
requirements for
pre-/post-test
counseling may
constrain
pharmacy-based
testing.
Cheek-swab tests
possible but no
blood may be
drawn or handled at
pharmacies.
Not provided for in
Law on Pharmacy
(2005); may be
permitted by
Ordinance on
Private Medical and
Pharmaceutical
Practice (Art. 18), if
pharmacies can be
considered medical
establishments.
Only local HIV/
AIDS prevention
agencies may do
testing;
pharmacies not
included.
Decree #1081 (December 22, 2011)
on licensing of pharmacies does not
allow pharmacies to conduct HIV
testing; additional license for medical
practice is required (FL #128 of
August 08, 2011; Decree #30 of
January 22, 2007).
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Table 2 Government laws and policies (Continued)
HBV/other
vaccination
Critical adult
vaccinations
permitted by
pharmacists
following
appropriate
training.
No legal
barriers; other
vaccinations
already
available in
pharmacies.
HBV vaccination
required for
children; Persons
with required
training and
certification may
provide vaccination.
No legal barriers
to pharmacies
providing HBV
or other
vaccinations.
However, it
would require
staff who have
appropriate
training, and
adequate
staffing levels.
The law does not
permit vaccinations
at pharmacies
unless the staff has
the proper
certification, such as
a nursing degree.
Not provided for in
Law on Pharmacy
(2005); may be
permitted by
Ordinance on
Private Medical and
Pharmaceutical
Practice (Art. 18) if
pharmacies can be
considered medical
establishments.
Vaccination is
not allow in
pharmac .
Vaccinat
requires nsed
medical ctor,
medical istant,
or nurse d
infrastru re to
store va e.
Decree #1081 (December 22, 2011)
on licensing of pharmacies does
not allow pharmacies to provide
vaccinations; additional license for
medical practice is required (FL #128
of August 08, 2011; Decree #30 of
January 22, 2007).
MMT/OST Federally
regulated;
methadone for
drug treatment
cannot be
dispensed in
pharmacies.
Federally
regulated;
methadone for
drug treatment
cannot be
dispensed in
pharmacies.
Office-based
physicians can
prescribe
methadone and
prescriptions are
treated like any
other but most
pharmacies are not
equipped to do
daily dosing.
Pharmacies can
dispense
methadone, but
regulations
restrict
prescription.
Methadone is a
“Control 1” drug
that requires a
prescription limited
to one-time admin-
istration, which ef-
fectively bars daily
dosing, and “Control
1” drugs can only
be handled by
major medical
institutions.
Prohibited by Law
on Pharmacy (2005)
Article 26.2 because
methadone is listed
as a habit-forming
drug, which phar-
macies are prohib-
ited from
dispensing.
Methado is
strictly c rolled
and can ly be
dispense n
governm t
approve rug
treatme
centers. annot
be dispe d in
pharmac .
Methadone is included in List I
of forbidden psychoactive agents
(FL on narcotics and psychoactive
agents of December 10, 1997).
Naloxone/
overdose
prevention/
rescue
Pharmacies
may dispense
through
standing
orders; training
is needed on
nasal delivery.
Pharmacies
may dispense
through
collaborative
practice
agreements
Limited liability for
licensed health
providers
prescribing and/or
distributing
naloxone.
Regulatory
barriers make
naloxone
unavailable to
individuals
through
prescription.
Pharmacies stock
naloxone as a
“Control 3” drug
that requires a
prescription that
may be filled 3
times and expires in
6 months.
Not provided for in
Law on Pharmacy
(2005); may be
permitted by
Ordinance on
Private Medical and
Pharmaceutical
Practice (Art. 18), if
pharmacies can be
considered medical
establishments.
Naloxon an
only be
dispense n
medical ilities.
Print ma ials
on over e
preventi can
be prov d in
pharmac .
Decree #2199-r (December 7, 2011):
naloxone is on the list of vitally
necessary and most essential
medications; but only medical
facilities are allowed to dispense
and administer and to provide
CPR if needed.
Abscess
treatment
Not currently
available but
no legal
barriers to
providing
information.
Pharmacies
cannot provide
medical or
clinical care
such as cutting
and draining.
Not currently
available but
no legal
barriers to
providing
information.
Pharmacies
cannot provide
medical or
clinical care
such as cutting
and draining.
No legal restrictions. No legal barriers. No legal barriers,
but only minor
wounds may be
treated at a
pharmacy.
Perforation or
cutting of any sort
in order to treat an
original wound not
permitted.
Not provided for in
Law on Pharmacy
(2005); may be
permitted by
Ordinance on
Private Medical and
Pharmaceutical
Practice (Art. 18), if
pharmacies can be
considered medical
establishments.
Pharmac can
provide nt
material nly.
Pharmacies can provide information and
medications.
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Table 2 Government laws and policies (Continued)
Brief
counseling/
materials
No legal
barriers except
to substance
abuse
treatment
counseling,
which is
covered by
state
regulations
No legal
barriers.
No legal barriers;
DPDP participating
pharmacies required
to provide health
information with
needle & syringe
sales
No legal barriers. No legal barriers. Should be
permissible.
Should be
permissible.
Pharmacies can provide such information.
Referrals No legal
restrictions.
No legal
restrictions.
No legal restrictions. No legal
restrictions.
No legal restrictions. No legal restrictions. No legal
restrictions.
No legal restrictions.
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Table 3 Corporate pharmacy policies (chain pharmacies)
Sites/
interventions
US (Boston) US (Providence) US (SF) Canada (Vancouver) Russia (St P)
Needle/
syringe
sales/
distribution
Corporate policy either
specifically allows for or is
silent on non-prescription
sales of syringes. Most
pharmacies sell needles/
syringes but the law provides
that sales of syringes is at the
discretion of the pharmacist.
Sales may be at the discretion of
the on-site pharmacy manager
Chains can enroll in Disease Prevention
Demonstration Programs so individual
stores can sell needles/syringes, but
implementation within chains has been
inconsistent.a
Most chains sell needles/
syringes but individual
stores can set policies;
many stores will not sell
Chains have no
objection to selling
needles/syringes but
would probably oppose
free distribution
Needle/
syringe
disposal
Pharmacies generally will not
accept used syringes for disposal.
Pharmacies generally will not
accept used syringes for disposal.
One chain allows; another prohibits Most chain pharmacies
have sharps containers and
accept full containers;
individual store policies
may differ
Requires additional
license for collecting
and storage of
epidemiologically
hazardous waste
HIV testing HIV testing is not available in pharmacies. HIV testing is not available in
pharmacies.
Some pharmacies in one chain offered
free HIV testing as part of National HIV
testing month
Not currently available Only at medically-
licensed facility
HBV/other
vaccination
A recent change in pharmacy policy (MDPH,
Drug Control Program and Immunization
Program, Joint Policy 2012–2) permits
administration of the hepatitis B vaccine in
pharmacies to adults by a qualified pharmacist.
Two major corporate chains have opened walk
in clinics for adult vaccination including hepatitis
B vaccines.
Pharmacies may offer any
vaccine including hepatitis B,
pneumonia, shingles, pertussis,
tetanus, meningitis and human
papillomavirus.
Most chains offer vaccinations Could be offered if staff
are properly trained
Only at medically-
licensed facility
MMT/OST Federal Law prohibits dispensing methadone at
retail pharmacies.
Federal Law prohibits dispensing
methadone at retail pharmacies.
Prescriptions could be filled but DOT
requires corporate approval
Regularly dispensed by
prescription
Methadone is a
prohibited psychoactive
agent
Naloxone/
overdose
prevention/
rescue
Prescriptions for naloxone may be filled. Also see collaborative practice
agreement comments above
(Table 2).
Prescriptions could be filled Individuals cannot obtain
by prescription; pharmacies
fill orders for clinics and
other authorized
organizations
Not generally stocked
by pharmacies
Abscess
treatment
Corporate policies support provision
of information
Corporate policies support
provision of information
Information about wound care
can be provided
Pharmacies refer customers
to health clinic
Pharmacies could offer
information; requires
display space
Brief
counseling/
materials
Corporate policies support the provision
of information.
Corporate policies support the
provision of information.
Information about medications
and health concerns can be provided
Some pharmacies may
have informational
materials, but most do not
Pharmacies could offer
information; requires
display space
Referrals Corporate policies support the provision
of information.
Corporate policies support the
provision of information.
Referrals can be made Pharmacies make referrals Pharmacies could offer
aLutnick A, Cooper E, Dodson C, Bluthenthal R, Kral AH. Pharmacy syringe purchase test of nonprescription syringe sales in San Francisco and Los Angeles in 2010. J Urban
Health 2012.doi:10.1007/s11524-012-9713-7.
H
am
m
ett
et
al.BM
C
H
ealth
Services
Research
2014,14:261
Page
7
of
11
http://w
w
w
.biom
edcentral.com
/1472-6963/14/261
Hammett et al. BMC Health Services Research 2014, 14:261 Page 8 of 11
http://www.biomedcentral.com/1472-6963/14/261There appear to be no legal barriers to needle/syringe
disposal in pharmacies except in St. Petersburg where a
special license for such disposal is required, and Ha Giang,
Vietnam where disposal of used needles/syringes at
pharmacies must comply with the Ministry of Health’s
regulations on management of medical wastes (Vietnam
Ministry of Health. Decision No. 43/2007/QD-BYT,
November 30, 2007). However, individual pharmacies
might refuse to offer disposal services. Cost may also play
a role in such decisions, as revealed in St. Petersburg:
It [syringe disposal] costs a lot. Not every medical
facility can afford waste disposal. –Department Head,
drug treatment facility
In San Francisco, some pharmacies’ reluctance to offer
required disposal services may explain their refusal to
join the DPDP, under which needles/syringes are sold
without prescription [17]. In Massachusetts, there is no
barrier to pharmacies accepting syringes for disposal,
but very few do, citing the high cost and safety concerns
with handling medical waste. The Massachusetts Depart-
ment of Public Health provides disposal “kiosks” but
none of these are placed in pharmacies. Biohazardous
waste containers and prepaid envelopes to mail used
syringes to a biohazardous waste company may be
purchased in some pharmacies.
In most sites, HIV testing in pharmacies is not legally
barred but cannot be provided without additional staff
training or certification. In Tijuana, only saliva-based
testing may be done in pharmacies because blood drawing
is prohibited. Similarly, St. Petersburg has an explicit pro-
hibition on blood/serum-based HIV testing in pharmacies
since this practice is restricted to licensed medical facil-
ities. Oral testing could be conducted at pharmacies in St.
Petersburg but individuals testing positive would require
confirmatory testing by the Municipal AIDS Center to
qualify for care and treatment. In Vancouver, strict
requirements for provision of pre/post-test counseling
limit the potential for offering HIV testing in pharmacies,
although access to testing has recently been expanded
through health clinics and community health centers.
In Boston, a recent change in pharmacy regulations
permits walk-in clinics to offer adult immunization,
including for hepatitis B. With the walk-in clinic infra-
structure in place, adding HIV testing may be feasible,
but is not currently permitted. Some pharmacy chains
operating in San Francisco allow vaccinations but others
do not. Several sites, including Boston, San Francisco,
Tijuana and Vancouver, require special training or certi-
fication for staff to administer vaccinations, while in St.
Petersburg pharmacies are prohibited from administer-
ing any vaccinations since this requires a medical license
and separate space in the facility:[Vaccination against hepatitis) is impossible [in
pharmacies] due to technical reasons. There are
numerous regulations that must be met according to
the “Sanitary Rules and Norms.” For instance, there
must be a separate room with specific technical
devices –Deputy Director, drug treatment facility.
Provision of methadone or other OST in pharmacies
faces serious legal and practical barriers. A pharmacy
worker in Ha Giang, Vietnam noted that
Vietnam Ministry of Health should enact legal
documents so we are allowed to sell… it will be
troublesome if selling is not permitted. Some specific
drugs only university-leveled pharmacists are permitted
to sell”. –pharmacy worker in Minh Khai ward
A number of the sites prohibit provision of OST in
pharmacies, while in several others special legal dispensa-
tion is needed for prescribing methadone or similar medi-
cations. In Russia, standard OST is prohibited by law in
all facilities. In Vancouver, OST in pharmacies is legally
permissible but a substantial proportion of methadone pa-
tients attend “private methadone clinics” [19]. In addition,
Vancouver physicians must receive an exemption under
the Controlled Drugs and Substances Act to prescribe
methadone or other medications used in OST.
The provision by pharmacies of naloxone for overdose
prevention and rescue also confronts diverse legal and
practical challenges. The difficulty or impossibility of
PWID getting to pharmacies to receive naloxone while
suffering from overdose has prompted the creation of
community-based overdose education and naloxone
access efforts in some places, designed to increase the
likelihood of timely emergency response [20]. Across all
sites, naloxone remains a prescription drug, used primarily
in clinical settings and by emergency medical staff and po-
lice, as recently proposed by New York’s Attorney General
[21]. Naloxone is seldom stocked in pharmacies. This in-
hibits efforts to utilize pharmacies as access points for
PWID and their caregivers [22].
In Boston, naloxone could be provided to PWID by
pharmacists under the existing “standing order”. This
order, issued in 2007 by the medical director of the over-
dose prevention program, provides that community mem-
bers and agency workers may be trained to provide nasal
naloxone to drug users for overdose prevention. In Provi-
dence, naloxone may be provided by pharmacies under
collaborative practice agreements with prescribers as part
of wider overdose prevention and naloxone access schemes
[23]. A collaborative practice agreement is a signed agree-
ment, entered into voluntarily, between a pharmacist with
advanced training and experience relevant to the scope of
collaborative practice and one or more physicians that
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pharmacist and physician(s) propose to engage.
Many San Francisco pharmacists said that they would
routinely fill prescriptions for naloxone. Under California
law (SB 767 [2007]), licensed health providers who pre-
scribe and/or distribute naloxone for emergency treatment
of drug overdose bear only limited liability. In 2010, this
limitation on liability was extended to lay providers of na-
loxone who have received appropriate training through a
program registered by a local health department [http://
legiscan.com/CA/text/AB2145/id/60864].
In St. Petersburg, naloxone may be dispensed and ad-
ministered only in licensed health care facilities. However,
naloxone is included in the “List of vitally necessary and
the most essential medicinal agents for 2012” (Decree of
the Government of RF#2199-r dated of December 7, 2011)
which ensures “physical and economical availability” of
certain medicinal products. Thus, pharmacies could be
compelled to make naloxone available should the appropri-
ate government agencies wish to promote its availability.
However, according to one drug treatment professional:
Although it should be legalized, as far as I know,
narcologist cannot prescribe naloxone to a drug
addict. …There is no indication in the labeling for
naloxone that would allow it to be used for overdose
prevention outside the clinical setting. It says that
[the] medication is to be used in medical facilities by
a physician. –Department Head, drug treatment
facility
According to laws or regulations in most sites, pharma-
cists cannot clean or dress abscesses because this would
constitute a practice of medicine prohibited to them. In
some countries, as well, providing such care could also
raise medical malpractice issues. However, in most sites
pharmacists could dispense antibiotics or ointments for
treatment of abscesses, with or without a prescription
depending on the country. In San Francisco, abscess treat-
ment in pharmacies may not be authorized by relevant
government agencies because such services are already
available at clinics and hospitals.
There are few if any legal or policy barriers to pharma-
cies providing information, materials, brief counseling and
referrals on any health issues, including HIV/AIDS, hepa-
titis, abscess treatment, overdose prevention and rescue,
and substance abuse treatment. The challenges that exist
arise largely from the practices and attitudes of individual
pharmacies and their staffs. In San Francisco, the needle/
syringe “buy study” found that many pharmacies partici-
pating in the DPDP were not providing written or oral
information on substance abuse treatment, HIV/HCV
testing, and safe disposal of used needles/syringes that is
required to accompany each needle/syringe sale [17].Discussion
This review of laws, policies, and practices presents a
mixed picture of the possibilities for implementing
pharmacy-based service enhancements for drug users.
Provision of informational materials and referrals in phar-
macies is legally permissible in all study sites and sale and
safe disposal of needles/syringes by pharmacies is legal in
almost all sites. Pharmacy provision of other services iden-
tified as most promising in the study, such as HIV testing,
hepatitis and other vaccinations, opioid substitution treat-
ment, provision of naloxone for treatment of opioid over-
dose, and abscess treatment face more serious and
pervasive legal and policy barriers.
We identified challenges to achieving a truly enabling
environment for the implementation of expanded phar-
macy services at all three levels of our conceptual model.
The most commonly identified challenges occur at the
macro-level where legal and policy provisions block
provision of some services and medications in pharmacies
and persistent stigma and its internalization by PWID re-
duce uptake of services that do exist. Lack of relationships
between pharmacies and HIV prevention and addiction-
related resources in the community and consequent lack
of consensus as to who should provide specific HIV-
related services also represent barriers to expansion of ser-
vices in pharmacies. In places dominated by private chain
pharmacies, skepticism that providing additional services
for PWID would translate into increased pharmacy profits
have also hindered offering such services.
At the meso-level, our study uncovered variations in
policy and practice related to services for PWID across
police agencies and pharmacy chains. For example, some
pharmacy chains narrowly define pharmacists’ roles and
responsibilities and limit interventions. Lack of sufficient
time and appropriate space may also limit possibilities
for expansion of services in pharmacies.
At the micro-level, differences in knowledge (such as
lack of understanding of addiction and harm reduction),
attitudes (such as stigmatizing PWID customers), and
behaviors (such as refusal to sell needles/syringes to
suspected PWID) of individuals pharmacists, pharmacy
workers, shift managers in large pharmacies, police offi-
cers, and other actors pose barriers to the expansion of
pharmacy-based services for PWID. In Russia, for
example, all aspects of life are highly bureaucratized and
officials and pharmacists feel that they must comply with
all regulations or risk punishment and damage to their
careers. They may also use the existence of prohibitory
rules and regulations to rationalize the denial of services
that they know or suspect would advance public health.
At the macro- level, where deficiencies and barriers in
governmental laws and policies may block implementa-
tion, stakeholders should advocate with relevant govern-
ment bodies for the needed legal and policy changes. For
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ment could be increased by inclusion of syringes in the fed-
eral list of mandatory medical products sold by pharmacies
[18]. Arguments from public health and safety are likely to
be the most persuasive and evidence should be marshaled
from places that have successfully and effectively expanded
pharmacy services such as needle/syringe sales.
Community-level stigma, discrimination, and resistance to
harm reduction interventions also inhibit PWID’s access to
all kinds of health services. Efforts are needed to convince
community members that those suffering from drug addic-
tion, a medical and psychosocial problem, would benefit from
services delivered in a respectful and non-discriminatory
manner and that such services contribute importantly to dis-
ease prevention without encouraging drug use.
In areas for potential expansion of pharmacy services in
which there has been little success to date, such as vaccin-
ation, MMT/OST, and naloxone provision, stakeholders
should assess the local situation and determine the
importance of pharmacies providing these services before
undertaking the difficult work needed to achieve the
changes in the legal and policy framework that would be
required. Laws limiting the liability of pharmacists who
prescribe naloxone to treat opioid overdose were adopted
in Massachusetts and Rhode Island since the completion
of our study. There are also efforts underway to make
naloxone available over the counter in the United States,
but this would require approval of the Food and Drug
Administration [http://drugtopics.modernmedicine.com/
news/otc-naloxone-its-possible].
Advocates should consider multiple stakeholder view-
points when designing policy reform efforts, including
possible incentive mechanisms to engage pharmacies and
other healthcare providers in services for drug users. No
legal or policy changes appear to be necessary to allow
expanded provision of counseling, informational materials,
and referrals but structural changes such as provision of
insurance coverage to compensate pharmacists for coun-
seling or brief interventions may be needed to assure
acceptability and sustainability of interventions [24,25].
Attention is also needed at the meso- and micro- levels.
Laws and policies are only as good as their implementation.
Serious gaps in the implementation of needle/syringe pro-
grams are well-documented and especially problematic in
settings with weak rule of law [26-29]. Police department
and pharmacy chain policies, and the knowledge, attitudes,
and practices of individual PWID, individual pharmacies/
pharmacists, and police officers should support rather than
undermine extant laws and policies. Pharmacists’ attitudes
and practices have been shown to influence provision of
needles/syringes, opioid substitution treatment, counseling,
and dissemination of HIV prevention and other health pro-
motion materials to PWID in Scotland [30], Australia
[31,32], and Estonia [9].Training for pharmacists and police officers could be con-
ducted to promote more supportive attitudes towards pro-
posed programs [28,30,33]. Systematic monitoring of police
abuse of drug users around pharmacies and other service
points may also help address structural barriers to service
access [34]. Programs are also needed to increase the self-
efficacy of PWID to improve their relationships with phar-
macists and thereby facilitate access to expanded services.
Overall, a considerable amount of advocacy will be
needed if pharmacies are to reach their potential as venues
for delivering services to drug users. This advocacy should
employ a public health perspective, demonstrate cost-
effectiveness of harm reduction interventions, and pro-
mote a human rights approach to the health problems of
marginalized populations.
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